Compare CHRD & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CHRD | ABVX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | France |
| Employees | 676 | 69 |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 7.2B |
| IPO Year | N/A | N/A |
| Metric | CHRD | ABVX |
|---|---|---|
| Price | $112.28 | $134.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $149.17 | $131.31 |
| AVG Volume (30 Days) | 804.9K | ★ 2.6M |
| Earning Date | 05-05-2026 | 03-23-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.56 | $52.14 |
| Revenue Next Year | N/A | $4,132.27 |
| P/E Ratio | $34.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.25 | $7.70 |
| 52 Week High | $151.95 | $148.83 |
| Indicator | CHRD | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 26.29 | 66.37 |
| Support Level | $86.73 | $107.67 |
| Resistance Level | $150.29 | $148.83 |
| Average True Range (ATR) | 3.99 | 7.44 |
| MACD | -1.49 | 4.14 |
| Stochastic Oscillator | 0.99 | 91.26 |
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.